Acerus Pharmaceuticals (OTCMKTS:TRLPF) and Diffusion Pharmaceuticals (NASDAQ:DFFN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, profitability, valuation and analyst recommendations.
Institutional & Insider Ownership
0.0% of Acerus Pharmaceuticals shares are owned by institutional investors. 5.8% of Diffusion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This is a summary of recent ratings and recommmendations for Acerus Pharmaceuticals and Diffusion Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Diffusion Pharmaceuticals has a consensus price target of $15.00, indicating a potential upside of 552.17%. Given Diffusion Pharmaceuticals’ higher probable upside, analysts clearly believe Diffusion Pharmaceuticals is more favorable than Acerus Pharmaceuticals.
This table compares Acerus Pharmaceuticals and Diffusion Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
Acerus Pharmaceuticals has a beta of 2.75, meaning that its share price is 175% more volatile than the S&P 500. Comparatively, Diffusion Pharmaceuticals has a beta of -0.37, meaning that its share price is 137% less volatile than the S&P 500.
Valuation and Earnings
This table compares Acerus Pharmaceuticals and Diffusion Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Acerus Pharmaceuticals||$6.44 million||3.95||-$8.71 million||N/A||N/A|
|Diffusion Pharmaceuticals||N/A||N/A||-$1.36 million||($17.09)||-0.13|
Diffusion Pharmaceuticals has lower revenue, but higher earnings than Acerus Pharmaceuticals.
Diffusion Pharmaceuticals beats Acerus Pharmaceuticals on 7 of the 10 factors compared between the two stocks.
Acerus Pharmaceuticals Company Profile
Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.
Diffusion Pharmaceuticals Company Profile
Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer. Its lead product candidate is transcrocetinate sodium, which has initiated Phase 3 trials for the treatment of glioblastoma multiforme (GBM); Phase 2 clinical trials for the treatment of pancreatic cancer; Phase 2/3 clinical trials for the treatment of metastatic brain cancer; and Phase 2 trial for the treatment of stroke. The company is also developing RES-529, a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of age-related macular degeneration; and is in pre-clinical development stage for the treatment of oncology primarily GBM. Diffusion Pharmaceuticals Inc. was founded in 2001 and is headquartered in Charlottesville, Virginia.
Receive News & Ratings for Acerus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acerus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.